TCM
MIST icon

Tekla Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

Tekla Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-253,610
Closed -$1.7M – 210
2020
Q4 		$1.7M Buy
253,610
+40,300
+19% +$270K 0.06% 164
2020
Q3 		$1.56M Hold
213,310
– – 0.06% 164
2020
Q2 		$806K Hold
213,310
– – 0.03% 201
2020
Q1 		$392K Sell
213,310
-533,343
-71% -$9.23M 0.02% 201
2019
Q4 		$12M Buy
746,653
+699,713
+1,491% +$12.4M 0.45% 49
2019
Q3 		$812K Sell
46,940
-3,060
-6% -$60.2K 0.04% 167
2019
Q2 		$1.36M Buy
+50,000
New +$1.03M 0.06% 153

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Tekla Capital Management's MIST Position: Q1 2021 in Review

Tekla Capital Management sold out of Milestone Pharmaceuticals (MIST) in Q1 2021, closing a stake of 253,610 shares — an estimated $1.7M sold.

Tekla Capital Management first reported a position in MIST in Q2 2019 and held it in 7 quarters. The position peaked at $12M in Q4 2019. 34 funds tracked by Wall St. Rank hold MIST as of Q1 2021.

  • Tekla Capital Management reported no remaining Milestone Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Tekla Capital Management sold 253,610 Milestone Pharmaceuticals shares in Q1 2021, an estimated $1.7M.
  • Tekla Capital Management first reported a position in Milestone Pharmaceuticals in Q2 2019 and held it in 7 quarters.
  • Tekla Capital Management's Milestone Pharmaceuticals position peaked at $12M in Q4 2019.
  • 34 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.